Navigation Links
Orthopedic Development Corporation's TruFUSE(R) Procedure Tops 1,750 Patients in First Year
Date:9/24/2007

CLEARWATER, Fla., Sept. 24 /PRNewswire/ -- Orthopedic Development Corporation, parent company to minSURG Corporation announced today that over 1,750 patients have received the TruFUSE posterior fusion procedure since its introduction last year. TruFUSE, one of the first intermediate surgical solutions to treat intractable back pain, has been in limited distribution.

The TruFUSE technique uses two small cork-shaped dowels made of human bone, called allografts, to stabilize vertebrae, and is used mostly in the lower, or lumbar, spine. The dowels are inserted using an entirely percutaneous or minimally invasive, minimally destructive technique between facet joints in the back to stop movement and pain. The TruFUSE technique is one of the first intermediate surgical options to fill the large void between traditional non-surgical back pain management and major spine fusion surgery. Two dowels are used to fuse one vertebra.

TruFUSE has been used on select patients since March 2006, and went into limited distribution in August 2006. With 30 distributors and over 100 hospital approvals and active surgeons, minSURG is preparing a broad market launch and expects to train and certify an additional 400 to 500 surgeons before the end of the year.

James Doulgeris, MinSURG's president and CEO, said, "TruFUSE represents a new, intermediate surgical option for many chronic back pain sufferers where there was none before. We are strongly encouraged by its rapidly broadening acceptance, particularly by patients, as an endorsement that validates TruFUSE's potential. With experienced management and systems in place to serve a much larger segment of the medical and healthcare community, both here and abroad, we are looking forward to the challenge of growing TruFUSE into a major surgical solution in the coming months."

TruFUSE is used to treat a variety of back problems, including augmentation of other procedures, for any location from C2-C3 to L5-S1. Compared to many existing methods, TruFUSE is generally less invasive, less destructive, less complicated, less expensive and subjects the patients to relatively minimal risk. It is also one of the few surgical options that can supplement or stand alone without precluding other options.

For more information on TruFUSE, please visit the Web site at http://www.trufuse.com or call (813) 318-0565 ext. 216.


'/>"/>
SOURCE Orthopedic Development Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India - Favored Orthopedics Surgery Destination
2. MDCT Compared to Digital Radiography in Orthopedic Patients
3. Drug Eluting Nanostructured Coatings Enable Targeted Drug Therapy for Orthopedic Patients
4. Developmental, neurologic problems common in extremely preterm infants
5. Cancer drugs in development nearly doubled since 1995
6. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
7. Role of zinc in development
8. Particulate matter affects lung development
9. Fossil teeth and human development
10. High development costs hinder entry of cancer super drugs into the market
11. Fireflies help speed development of new drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced the ... solution for colleges and universities at the APPA 2017 Annual Conference and ... and tobacco smoke odors without the use of harsh chemicals, Fresh Wave IAQ Smoke ...
(Date:7/21/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has written a ... and pleads with world leaders to be more open about positive changes. Yisrayl says the ... there is a peaceful and positive way to solve all; yes, all issues, and he ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... West Dermatology ... Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s ... years of experience in dermatology, skin cancer , and more. She graduated from ...
(Date:7/20/2017)... Va. (PRWEB) , ... July 20, 2017 , ... ... McCarter, MD, has joined JenCare Senior Medical Center as Richmond Chief Medical ... Virginia School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... telemedicine platform, in which their iMedSecure™ comes included with each system installation. ... live images to remote participants for real-time collaboration and immediate decision-making requirements. ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... manufacturing network, the Company will be ceasing operations and ... Huntsville, Alabama . The closure of the facilities ... to 18 months. The Huntsville ... products and these restructuring actions are intended to better ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
Breaking Medicine Technology: